Once again, a collection of links, blogs, and articles I have been reading recently and should be of general interest to the biotech investor or enthusiast. The authors and "passers on" of these links are great candidates for your Twitter or RSS follow list as well.
(continue reading for full "link fest")
(continue reading for full "link fest")
Once again, a collection of links, blogs, and articles I have been reading recently and should be of general interest to the biotech investor or enthusiast.
Progress and Promise: The Current Status of Spinal Muscular Atrophy Therapeutics
Good background if you are interested in the upcoming ISIS-BIIB data release (h/t @chasingthealpha)
Sequester Cuts Comes Down Hard on Scientific, Medical Research
As Sequestration Dawns, FDA Supporters Scramble to Ease Woes of Drug Reviews
Fierce Biotech
There Should be Grandeur: Basic Science in the Shadow of the Sequester
Scientific American - Tom Levenson (h/t @vero_greenwood)
FDA Reform Can Lift U.S. Economy
Bloomberg, h/t @MatthewHerper - interesting read even though the article is deeply flawed and I disagree with a number of their conclusions/suggestions
Finding Parallels in Baseball and Drug Development
Xconomy - Kyle Serikawa
FDA Breakthrough Therapy Designations - FAQ's and Statistics on Applications, Approvals, and Rejections
Great new feature on official FDA website (h/t @scrippdonnadc and @pinksheetsutter)
Inhibitors of Apoptosis Target one of the Hallmarks of Cancer
Biotech Strategy Blog by Pieter Droppert (@3NT)
Updates on drugs targeting IAP including from Roche/Genentech, Curis CRIS, Astex Pharma ASTX, Novartis NVS.
Cave Explorer Hunts Antibiotics1,600 Feet Down
Bloomberg - Meg Tirrell (h/t @bradloncar and re CBST, OPTR, etc in the antibiotics space)
FDA wants to regulate drug firms on the internet and it's targeting Facebook "Likes"
Forbes - Scott Gottlieb
More on the Shelf
Nature blogs - Adam Scott Bristol
What happens after a biotech company files a S-3 statement ("shelf")? Detailed analysis.
Roche peels back curtain on clinical trial data
Pharmalot - Ed Silverman. A second big pharma says they will make all data public. An important trend to monitor, with far-reaching potential consequences
Progress and Promise: The Current Status of Spinal Muscular Atrophy Therapeutics
Good background if you are interested in the upcoming ISIS-BIIB data release (h/t @chasingthealpha)
Sequester Cuts Comes Down Hard on Scientific, Medical Research
As Sequestration Dawns, FDA Supporters Scramble to Ease Woes of Drug Reviews
Fierce Biotech
There Should be Grandeur: Basic Science in the Shadow of the Sequester
Scientific American - Tom Levenson (h/t @vero_greenwood)
FDA Reform Can Lift U.S. Economy
Bloomberg, h/t @MatthewHerper - interesting read even though the article is deeply flawed and I disagree with a number of their conclusions/suggestions
Finding Parallels in Baseball and Drug Development
Xconomy - Kyle Serikawa
FDA Breakthrough Therapy Designations - FAQ's and Statistics on Applications, Approvals, and Rejections
Great new feature on official FDA website (h/t @scrippdonnadc and @pinksheetsutter)
Inhibitors of Apoptosis Target one of the Hallmarks of Cancer
Biotech Strategy Blog by Pieter Droppert (@3NT)
Updates on drugs targeting IAP including from Roche/Genentech, Curis CRIS, Astex Pharma ASTX, Novartis NVS.
Cave Explorer Hunts Antibiotics1,600 Feet Down
Bloomberg - Meg Tirrell (h/t @bradloncar and re CBST, OPTR, etc in the antibiotics space)
FDA wants to regulate drug firms on the internet and it's targeting Facebook "Likes"
Forbes - Scott Gottlieb
More on the Shelf
Nature blogs - Adam Scott Bristol
What happens after a biotech company files a S-3 statement ("shelf")? Detailed analysis.
Roche peels back curtain on clinical trial data
Pharmalot - Ed Silverman. A second big pharma says they will make all data public. An important trend to monitor, with far-reaching potential consequences
RSS Feed
